{
    "clinical_study": {
        "@rank": "97564", 
        "acronym": "ACH", 
        "arm_group": {
            "arm_group_label": "BMN 111 - Subcutaneous Injection", 
            "arm_group_type": "Experimental", 
            "description": "111-202 is an open-label sequential cohort dose-escalation study. BMN 111 will be administered as a morning dose in one of the following daily dosing regimens:\n\u2022 Cohort 1: 2.5 microgram/kg, Cohort 2: 7.5 microgram/kg, and Cohort 3: 15.0 microgram/kg."
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in\n      children with achondroplasia.  The primary objective is to assess the safety and\n      tolerability of daily BMN 111 administered to children with achondroplasia."
        }, 
        "brief_title": "A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Achondroplasia", 
        "condition_browse": {
            "mesh_term": "Achondroplasia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Parent(s) or guardian(s) are willing and able to provide written, signed informed\n             consent after the nature of the study has been explained and prior to performance of\n             any research-related procedure. Also, subjects under the age of 18 are willing and\n             able to provide written assent (if required) after the nature of the study has been\n             explained and prior to performance of any research-related procedure.\n\n          -  Are 5 to 14 years old, inclusive\n\n          -  Have ACH, documented by clinical grounds and confirmed by genetic testing\n\n          -  Have at least a 6-month period of pretreatment growth assessment in Study 111-901\n             immediately before study entry\n\n          -  Females of childbearing potential must have a negative pregnancy test at the\n             Screening Visit and be willing to have additional pregnancy tests during the study\n\n          -  If sexually active, willing to use an acceptable method of contraception while\n             participating in the study\n\n          -  Are ambulatory and able to stand without assistance\n\n          -  Are willing and able to perform all study procedures as physically possible\n\n          -  Parents or caregivers are willing to administer daily injections to the subjects\n\n        Exclusion Criteria:\n\n          -  Have hypochondroplasia or short stature condition other than ACH (eg, trisomy 21,\n             pseudoachondroplasia)\n\n          -  Have any of the following:\n\n               -  Hypothyroidism\n\n               -  Insulin-requiring diabetes mellitus\n\n               -  Autoimmune inflammatory disease\n\n               -  Inflammatory bowel disease\n\n               -  Autonomic neuropathy\n\n               -  Acute illness associated with volume dehydration (eg, nausea, vomiting,\n                  diarrhea)\n\n          -  Have an unstable condition likely to require surgical intervention during the study\n             (including progressive cervical medullary compression)\n\n          -  Growth plates have fused\n\n          -  Have a history of any of the following:\n\n               -  Renal insufficiency\n\n               -  Anemia\n\n               -  Baseline systolic BP < 75 mm Hg or recurrent symptomatic hypotension  (defined\n                  as episodes of low BP generally accompanied by symptoms i.e., dizziness,\n                  fainting) or recurrent symptomatic orthostatic hypotension\n\n          -  Cardiac or vascular disease, including the following:\n\n               -  Cardiac dysfunction (abnormal echocardiogram [ECHO] including left ventricle\n                  [LV] mass) at Screening Visit\n\n               -  Hypertrophic cardiomyopathy\n\n               -  Congenital heart disease with ongoing cardiac dysfunction\n\n               -  Cerebrovascular disease, aortic insufficiency\n\n               -  Clinically significant atrial or ventricular arrhythmias\n\n          -  Have an ECG showing any of the following:\n\n               -  Right or left atrial enlargement or ventricular hypertrophy\n\n               -  PR interval > 200 msec\n\n               -  QRS interval > 110 msec\n\n               -  Corrected QTc > 440 msec\n\n               -  Second- or third-degree atrioventricular block\n\n          -  Demonstrate vitamin D deficiency (i.e., concentration of 25-hydroxy-vitamin D in the\n             blood serum occurs at 12 ng/mL or less)\n\n          -  Require any investigational agent prior to completion of study period\n\n          -  Have received another investigational product or investigational medical device\n             within 30 days before the Screening visit\n\n          -  Pregnant or breastfeeding at the Screenng Visit or planning to become pregnant (self\n             or partner) at any time during the study\n\n          -  Current treatment with antihypertensive medications, ACE inhibitors, angiotensin II\n             receptor blockers, diuretics, beta-blockers, calcium-channel blockers, cardiac\n             glycosides, systemic anticholinergic agents, any medication that may impair or\n             enhance compensatory tachycardia, drugs known to alter renal function\n\n          -  Have been treated with growth hormone, IGF-1, or anabolic steroids in the previous 6\n             months or long-term treatment (> 3 months) at any time\n\n          -  Have had regular long-term treatment (> 1 month) with oral corticosteroids (low-dose\n             ongoing inhaled steroid for asthma is acceptable)\n\n          -  Concomitant medication that prolongs the QT/QTc interval within 14 days or 5\n             half-lives, whichever is longer, before the Screening visit\n\n          -  Unwilling to temporarily discontinue CPAP use for 2 days prior to Screening visit if\n             applicable\n\n          -  Have used any other investigational product or investigational medical device for the\n             treatment of ACH or short stature\n\n          -  Have had bone-related surgery or expected to have bone-related surgery during the\n             study period. Subjects with previous limb-lengthening surgery may enroll if surgery\n             occurred at least 18 months prior to the study and healing is complete without\n             sequelae\n\n          -  Have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at least 3x\n             upper limit of normal (ULN) or total bilirubin at least 2x ULN\n\n          -  Have known hypersensitivity to BMN 111 or its excipients\n\n          -  Has a condition or circumstance that, in the view of the Investigator, places the\n             subject at high risk for poor treatment compliance or for not completing the study\n\n          -  Concurrent disease or condition that, in the view of the Investigator, would\n             interfere with study participation or safety evaluations, or would predispose the\n             subject to hypotension (such as recent gastroenteritis or dehydration for any reason)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055157", 
            "org_study_id": "111-202", 
            "secondary_id": "2013-004137-32"
        }, 
        "intervention": {
            "arm_group_label": "BMN 111 - Subcutaneous Injection", 
            "description": "BMN 111 will be administered daily for 6 months in an open-label sequential dose escalation fashion.", 
            "intervention_name": "BMN 111", 
            "intervention_type": "Drug", 
            "other_name": "Modified recombinant human C-type natriuretic peptide"
        }, 
        "intervention_browse": {
            "mesh_term": "Natriuretic Peptide, C-Type"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Achondroplasia", 
            "Dwarfism", 
            "Bone Diseases, Developmental", 
            "Bone Diseases"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232-2578"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3052"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75015"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE1 9RT"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "France", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia", 
        "overall_contact": {
            "email": "rmcmahon@bmrn.com", 
            "last_name": "Robin McMahon, MPH"
        }, 
        "overall_official": {
            "affiliation": "BioMarin Pharmaceutical", 
            "last_name": "Medical Director, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Australia: Human Research Ethics Committee", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety evaluations by indicence of adverse events, serious adverse events, laboratory test results (urinaysis, chemistry, hematology), clinically significant changes in vital signs, physical examination, ECG and ECHO results, imaging, and anti-BMN 111 immunogenicity assessments.", 
            "measure": "Safety Measures", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 6 months. Following completion of study (Month 6), a safety follow up visit will be conducted (Month 7)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Efficacy will be assessed by change from baseline in height growth velocity (annualized to cm/yr), absolute growth, subject growth compared with ACH and non-ACH standardized pediatric growth curves, and change in body proportions. These will be assessed by anthropometric measurements and measurement ratios.", 
            "measure": "Efficacy measure", 
            "safety_issue": "No", 
            "time_frame": "Approximately 6 months"
        }, 
        "source": "BioMarin Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioMarin Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}